Haemoglobinopathies Market s expected to reach $8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022

Global Hemoglobinopathie market is accounted for $4.6 billion in 2015 and is expected to reach $8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022. Increasing incidences of hemoglobin disorders with strong product portfolio for sickle cell anemia such as HQK-1001 and Luspatercept, government’s awareness programs and advanced diagnostics and therapeutics will fuel the market growth. Research & development and growth across developed and developing economies will provide opportunity for the market growth. Instrumentation cost and expertise required for LC MS/MS, molecular identification of the alpha and beta chain mutations are some of the factors that impede the market growth.

Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period. The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market. Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth.

Request for Sample Report: https://www.researchbeam.com/haemoglobinopathies-global-outlook-2016-2022-market/request-sample

Some of the key players in global Hemoglobinopathie market are Gamida Cell,Alnylam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma.

Disorders Covered:
• Sickle Cell Disease
• Haemoglobin variants diseases
o Haemoglobin C disease
o Haemoglobin S-C disease
• Thalassemia
Drugs Covered:
• NiCord
• ZFP Transcription Factors

Do Inquire About Report: https://www.researchbeam.com/haemoglobinopathies-global-outlook-2016-2022-market/enquire-about-report

What our report offers:
– Market share assessments for the regional and country level segments
– Market share analysis of the top industry players
– Strategic recommendations for the new entrants
– Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
– Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
– Strategic recommendations in key business segments based on the market estimations
– Competitive landscaping mapping the key common trends
– Company profiling with detailed strategies, financials, and recent developments
– Supply chain trends mapping the latest technological advancements.

About Us

Research Beam is a high end and wide online market for market research reports that contain detailed and rational market research. Research Beam is a one stop report destination that offers clients well drafted and accurately analyzed report with insightful data.

Reports available on our data base are holistic in nature and will help to understand your related market effectively. Our market research reports are of the highest quality with deep dive analytical view that offer clients incisive perspective about the market. With the help of our reports, clients can easily understand the dynamic nature of their respective markets and then implement result oriented decisions.

Contact Us:

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

Direct :  +1-971-202-1575

Designed by CyFocus.com
Powered by CyFocus.net
%d bloggers like this: